						Shee	t <u>1</u>		ובטונטבו			RF
					ATTY. DOCKET NO.			AF	PETGA	TION	e	<u> </u>
D E NOT	0F DEF		V ADDI IOANIT		4821-438			no	3/987	930⊂	<u>> [</u>	<u>"</u>
PEDIST	OF REF Use	ERENCES CITED B' e several sheets if neces			APPLICANT				600/290	7002	} <	7 7
1 5 2002 6					JERUSSI et al.			т-	23		+	+
Ĕ					FILING DATE November 16, 2001				300 0 514			
TRADEMARK			U.S. PA	TENT DO	CUMENTS			•				
'EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	-	CLAS	s	SUBC	LASS	FILING D IF APPROPR	DATE
W	AA	5,763,493	6/9/98	Ruff e	at al		<u> </u>				APPROPR	RIATE
	AB		5/19/98	Pinsk			-					
	AC	5,753,712		1	<u> </u>		\dashv		$\neg \dagger$			
		5,731,000	3/24/98	Ruff e			\dashv					_
	AD	5,541,231	7/30/96	Ruff e			\dashv		-+			
	AE	5,512,593	4/30/96	Dante			+		\dashv			
	AF	5,447,948	9/5/95	Seiby	l et al.		+	_	\dashv			
	AG	5,427,798	6/27/95	Ludwi	g et al.		-+	\dashv	\dashv			
	AH	5,358,970	10/25/94	Ruff e	et al.		_		_		-	
	Al	5,217,987	6/8/93	Berge	er				_		<u> </u>	
	AJ	4,935,439	6/19/90	Kashr	man et al.							
	AK	4,935,429	6/19/90	Dacki	s et al.							
	AL	4,895,845	1/23/90	Seed								
	AM	4,868,344	9/19/89	Brown	<u></u>							
	AN	4,835,147	5/30/89	Robe	rts							
	AO	4,798,826	1/17/89	Peck								
	AP	4,769,027	9/6/88	Baker	et al.							
	AQ	4,687,660	8/18/87	Baker	•		1					
	AR	4,656,026	4/7/87		ıan et al.		\exists					
	AS	4,571,395	2/18/86	Peck			\neg					
	AT	4,507,323	3/26/85	Stern								
	AU	4,438,138	3/20/84	Stern				\dashv				
	AV	4,435,449	3/6/84				+					
	AW			Stern			\top	\dashv				
		4,425,363	1/10/84	Stern			_	\dashv		\dagger		
3/-/	AX	4,393,078	7/12/83	Peck						1		
	AY	4,356,165	10/26/82		ay et al.					1		
\Jb	AZ	4,355,179	10/19/82	I Findle	ay et al.					V		

		HI STATE OF THE ST			Shee	t _	2	_	<u>7</u> ∰	֓֞֞֜֜֜֝֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֡֓֓֓֓֓֓֡֓֓֡֓֡֓֡֓֡	RECEVE
The state of the s	ВА	4,347,382 TRANS	8/31/82	Scharver			V	妥	0 /2	<u>ַ</u>	П
	ВВ	4,347,257	8/31/82	Stern			Ε_	60	7007	V	
	вс	4,347,178	8/31/82	Findlay et al.				1600/2900	7		"
	BD	4,347,177	8/31/82	Phillips				8			
	BE	4,347,176	8/31/82	Mehta							
	BF	4,008,719	2/22/77	Theeuwes et al.							
	BG	3,960,927	6/1/76	Metcalf et al.							
	ВН	3,916,899	11/4/75	Theeuwes et al.							
	ВІ	3,885,046	5/20/75	Mehta							
	BJ	3,845,770	11/5/74	Theeuwes et al.							
	вк	3,819,706	6/25/74	Mehta							
	BL	3,630,200	12/28/71	Higuchi							
	ВМ	3,622,675	11/23/71	Koppe et al.							
y.	BN	3,598,123	8/10/71	Zaffaroni							
	во	3,536,809	10/27/70	Applezweig							
	ВР	RE 33,994	7/14/92	Baker et al.		1					
			FOREIGN F	ATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		C	CLASS	SUBC	CLASS	TRANS	NO
Van de la constant de	BQ	WO 95/22324	8/24/95	PCT				T		123	
1	BR	WO 94/20100	9/15/94	PCT							
	BS	WO 94/04138	3/3/94	PCT						-	
	вт	WO 93/21917	11/11/93	PCT						,	
	BU	WO 91/11184	8/8/91	PCT							
	BV	WO 92/19226	11/12/92	PCT				П			
	ВW	WO 95/03791	2/09/95	PCT							
	вх	WO 96/39133	12/12/96	PCT							
	BY	WO 97/29735	8/21/97	PCT							
	BZ	WO 98/50044	11/12/98	PCT				П			
	CA	WO 99/37305	7/29/99	PCT				П			
	СВ	0 467 488	1/22/92	EPO							
	СС	0 171 227	2/12/86	EPO							
/	CD	0 118 036	9/12/84	EPO				П			
12	CE	977778	11/11/75	CA							



FEB 2 0 2002

SheFECHBCENTER 1600/2900

No.		CF	977777	11/11/75	CA				
V		CG	63-91352	4/22/88	JP	_			
	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
K		CH Ascher, J.A. et al., 1995, "Bupropion: a review of its mechanism of antidepressant activity", J. Clin. Psych. <u>56</u> :395-401.							
		CI	Bannon et al., 1998, "Broad-spectrum, non-opoid analgesic activity by selective modulation of						
		CJ	Bischoff et al., 1984, ' treatment', Eur. J. Ph		ges of rat striatal dopamine receptor in	n vivo afte	r acute bu	ıpropi	on
		СК	Blondel-Hill et al., 199	3, "Treatmen	t of the chronic fatigue syndrome", Dr	ugs 46(4)	:639-651.		
		CL	Borowski, T.B. et al., related seizures", Bra	•	etamine and antidepressant drug effects 30:607-610.	cts on GA	BA- and N	ADM	
	<u>-</u>	СМ	Calabrese, J.R. et al.,	1991, "Treat	ment of depression", Primary Care <u>18</u>	<u>(2):421-4</u>	33.		
	Castaldi, G. et al., 1987, "Tartaric acid, an efficient chiral auxiliary: new asymmetric synt alkyl-2-arylacetic acids", J. Org. Chem. <u>52</u> :3018.					c synthes	is of 2	<u></u> -	
		со	Castello, R.A. and Ma	ttocks, A.M.,	J. Pharm. Sci. 51(2):106-108 (1962).				
		СР	Charney, D.S. et al, 1983, "Monoamine receptor sensitivity and depression: clinical studies of antidepressant effects on serotonin and noradrenergic function," Psychopharmacol. Bull 19(3):490.						
		cq	Clay et al., 1988, "Clir Psycopharma. Bull. <u>2</u>		ropsychological effects of the novel ar	ntidepress	ant bupro	pion",	
		CR	Conners, K.C. et al., 'Am. Acad. Child Adol		oion hydrochloride in attention deficit c r. <u>34(10)</u> :1314-1321.	lisorder w	ith hypera	ctivity	r", J.
		cs	Cooke C.E., 1997, "TI Practice 10(5):329-33	•	vances in the treatment of cigarette a	ddiction",	J. Pharma	асу	
		СТ			e that the acute behavioral and electr ted by a noradrenergic mechanism", N				ЭУ
		CU	Cooper, T.B. et al., Ar	nalytical psycl	nopharmacology: NY State Psychiatri	c Institute	pp. 1-3.		
		CV			Implications of chirality and geometric polites", Chirality 1:99-120.	isomeris	ms in som	ne	
		cw	Crenshaw et al., 1987 Ther. 13(4):239-252.	, "Pharmacol	ogical modification of psychosexual d	ysfunctior	n", J. Sex.	Marit	al
		сх		_	antidepressants to human brain rece armacol. 114:559-565.	ptors: foc	us on new	er	
	3	CY	·		n chronic low back pain", J. Clin. Psyc	hiatry 55	(8):362.		




FEB 2 0 2002 Sheet 4 of 7 TECH CENTER 1600/2000

		TECH CENTER 1600/2900
1	cz	Dilsaver, S.C. et al., 1992, "The efficacy of bupropion in winter depression: results of an open trial", J. Clin. Psychiatry 53(7):252-255.
	DA	Eliel, E.L., 1962, Stereochemistry of Carbon Compounds, McGraw-Hill, NY.
	DB	Ferris, R.M. et al., 1983, "Studies of bupropion's mechanism of antidepressant activity", J. Clin. Psychiatry <u>44(5)</u> :74-78.
	DC	Ferris & Beaman, 1983, "Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic β -adrenergic, serotonergic (5-HT ₂), α_2 -adrenergic, imipramine and dopaminergic receptors in brain", Neuropharmacol. 22(1):1257-1267.
	DD	Ferry, L.H. et al, 1992, "Enhancement of smoking cessation using the anti-depressant bupropion hydrochloride" (abstract) Circulation 86:671.
	DE	Ferry, L.H. et al., 1994, "Efficacy of bupropion for smoking cessation in non-depressed smokers," J. Addict, Dis. 13:A9.
	DF	Fisher, R.S., 1989, "Animal models of the epilepsies", Brain Res. Reviews 14:245-278.
	DG	Foote et al., 1984, "Proconvulsant effect of morphine on seizures induced by pentylenetetrazol in the rat", 105:179-184.
	DH	Garland et al., 1998, "Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats", J. Psychopharmacology 12(4):385-395.
	DI	Goetz et al., 1984, "Bupropion in Parkinson's Disease," 34:1092-4.
	DJ	Goodnick, P.J., 1994, "Pharmacokinetic optimisation of therapy with newer antidepressants", Clin. Pharmacokinet. <u>27(4)</u> :307-330.
	DK	Goodnick, P.J. & Sandoval, R., 1993, "Psychotropic treatment of depression: results of an open trial", J. Clin. Psych. 54(1):13-20.
	DL	Green, A.R. & Murray, T.K., 1989, "A simple intravenous infusion method in rodents for determining the potency of anticonvulsants acting through GABAergic mechanisms", J. Pharm. Pharmacol. 41:879-880.
	DM	Grimes et al., 1996, "Spontaneous orgasm with the combined use of bupropion and sertraline", Soc. Biol. Psych. <u>40</u> :1184-1185.
	DN	Handbook of Pharmaceutical Excipients, 2nd ed., Wade and Willer eds., pp. 257-259 (1994).
	DO	Hsyu, P.H. et al., 1997, "Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers", J. Clin. Pharmacol. 37(8):737-743.
	DP	Hsyu, P.H. et al., 10 November 1997 Chemical Abstracts 127(19): Abstract no. 257089; Columbus, Ohio.
	DQ	Janowsky, A., et al., J. Neurochem. 46:1272-1276 (1986).
M	DR	Kelley, J.L. et al., 1996, "(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake", J. Med. Chem. 39:347-349.



FEB 2 0 2007 SHECH CENTER 7600/2900

			JEON CLIVIER 1800/2900
12		DS	Ketter, T.A. et al., 1995, "Carbamazepine but not valproate induces bupropion metabolism", J. Clin. Psycopharmacol. <u>15(5)</u> :327-333.
1		DΤ	Laizure, S.C. et al., 1985, "Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose", Clin. Pharmacol. Ther. 38:586-589.
		DU	Lief, H.I., 1996, "Bupropion treatment of depression to assist smoking cessation", Am. J. Psychiatry 153(3):442.
		DV	Little, K.Y. et al., 1993, "[125 l]RTI-55 binding to cocaine-sensitive dopaminergic and serotonergic uptake sites in the human brain", J. Neurochem. 61:1996-2006.
		DW	Martin, P, et al., 1990, "Antidepressant Profile of Bupropion and Three Metabolites in Mice," Pharmacopsychiatry 23:187-194.
		DX	McNamee et al., 1986, "Stimulation of substrate oxidation in rat hepatic mitochondria following pretreatment with appetite modifying drugs", J. Pharm. Pharmacol. 37:147.
		DY	Merskey, H., 1965, "The effect of chronic pain upon the response to noxious stimuli by psychiatric patients," J. Psychosom. Res. 8:405-419.
		DZ	Michell, G.F. et al., 1989, "Effect of bupropion on chocolate craving", Am. J. Psychiatry 146(1):119-120.
		EA	Michell, G.F. et al., 1989, "Dr, Mitchell and associates reply", Am. J. Psychiatry 146(8):1089.
		EB	Moisset, B., et al., Brain Res. 92:157-164 (1975).
		EC	Moret, C. & Brile, M., 1988, "Sensitizing of the response of 5-HT autoreceptors to drugs modifying synaptic availability of 5-HT", <u>27(1)</u> :43-49.
		ED	Musso et al., 1993, "Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion", Chirality 5:495-500.
		EE	Musso et al., 1997, "Synthesis and Evaluation of the Anticonvulsant Activity of a Series of 2-Amino-Phenyl-1-Propanols Derived from the Metobolites of the Antidepressant Bupropion," Bioorganic & Medical Chemistry Letters, Vol. 7 No 1, pp 1-6, 1997.
		EF	Neurology, Official Journal of American Academy of Neurology, August 1984, volume 34, Number 8
		EG	Nomikos et al., 1992, "Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum", Neuropsychopharmacology 7(1):7-14.
		EH	Nutt, D.J. et al., 1981, "Studies on the postietal rise in seizure threshold, " Eur. J. Pharmacol. 71:287-295.
	1	EI	Nutt, D.J. Et al, 1980, "On the measurement in rats of the convulsant effect of drugs and the changes which follow electroconvulsive shock," Neuropharmacology 19:1017-1023.
		EJ	Olsen et al., 1985, "Benzodiazepine/γ-aminobutyric acid receptor deficit in the midbrain of the seizure-susceptible gerbil", PNAS USA 82:6701-6705.
W	3	EK	Pearlstein et al., 1997, "Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder", J. Clin. Psychopharmacol. 17(4):261-266.



TECH CENTER 1600/2900 Sheet __6__ of _7_



		ATEM ATME
[a	EL	Perovic, S. and Mueller, W.E.G., Brain Res. 92:157-164 (1995)
0	EM	Physician's Desk Reference®, 1998, pages 1120-1127.
	EN	Popli, A.P. et al., 1994, "Antidepressant-associated seizures", J. Clin. Psych. <u>55(6)</u> :267.
	EO	Popli, A. et al., 1995, "Bupropion and anticonvulsant drug interactions", Annals of Clin. Psychiatr. 7(2):99-101.
	EP	Posner, J. et al., 1985, "The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses", Eur. J. Clin. Pharmacol. 29:97-103.
	EQ	Potter, W.Z. & Manji, H.K., 1990, "Antidepressants, metabolites, and apparent drug resistance", Clin. Neuropharmacol. 13(1):S45-S53.
	ER ·	Remingtons: The Practice of the Science and Pharmacy, 19th ed., Gennaro, ed., p. 1625 (1995).
	ES	Rose, J.E., 1996, "Nicotine addiction and treatment", Annu. Rev. Med. 47:493-507.
	ET	Rosenstein, D.L. et al., 1993, "Seizures associated with antidepressants: a review", J. Clin. Psychiatry <u>54(8)</u> :289-299.
	EU	Rudorfer, M.V. et al., 1994, "Comparative tolerability profiles of the newer versus older antidepressants", Drug Safety 10(1):18-46.
	EV	Schroeder, D.H., 1983, "Metabolism and kinetics of bupropion", J. Clin. Psychiatr. 44(5):79-81.
	EW	Schroedger, D.H. et al., 1979, "The isolation and identification of some basic urinary metablites of bupropion - HCL in man", The Pharmacologist 21(3):191.
	EX	SCRIP Bupropion Sustained Release (SR) for Smoking Cessation, 12/18/96.
	EY	SCRIP Itraconazole for 'pulse" dosing of onychomycosis, 12/18/96.
	EZ	Scrip's New Product Review, No. 50 Bupropion, PJB Publications: United Kingdome, August, 1990.
	FA	Stathis, M. et al., 1995, "Rate of binding of various inhibitors at the dopamine transporter in vivo", Psychopharmacol. <u>119</u> :376-384.
	FB	Storrow, A.B., 1994, "Bupropion overdose and seizure", Am. J. Emerg. Med. 12:183-184.
	FC	Suckow, R.F. et al.,1986, "Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs", Drug Metab. Disposit. 14(6):692-697.
	FD	Suckow, R.F. et al., 1997, "Enantiomeric determination of the phenylmorpholinol metabolite of bupropion in human plasma using coupled achiral-chiral liquid chromatography", Biomedical Chromatog. 11:174-179.
	FE	Sulser, F., 1983, "Molecular mechanisms in antidepressant action," <u>Psychopharmacol.</u> Bull. 19(3):300.
	FF	Sweet, R.A. et al., 1995, "Pharmacokinetics of single- and multiple- dose bupropion in elderly patients with depression", J. Clin. Pharmacol. 35:876-884.
W	FG	Testa B. and Trager, W.F., 1990, "Racemates Versus Enantiomers in Drug Development: Dogmatism or Pragmatism?" Chirality 2:129-133.





FEB 2 0 2002

TECH CENTER 1660/2900

(g)	Vassout, A. et al., 1993, "Regulation of dopamine receptors by bupropion: comparison with antidepressants and CNS stimulants", J. Receptor Res. 13(1-4):341-354.							
	FI	Ward, N.G., 1990, The Management of Pain, Second Edition, Vol. 1, Chapter 18 (eds.) Bonica, J.J. pp. 310-319.						
	FJ	Ward, R. et al., 1971, "Asymmetric audiogenic seizures in mice: a possible analogue of focal epilepsy", Brain Res. 31:207-210.						
	FK	Welch, R.M. et al., 1987, "Pharmacological significance of the species differences in bupropion metabolism", Nenobiotica 17(3):287-298.						
	FL	Wilen, S.H., 1972, <u>Tables of Resolving Agents and Optical Resolutions</u> , Univ. of Notre Dame Press, Notre Dame, IN.						
	FM	Wright et al., 1985, "Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects", J. Clin. Psych. 46(1):22-25.						
1	Zarrindast et al., 1988, "Anorectic and behavioral effects of bupropion", Gen. Pharmacology 19(2);201-204.							
EXAMINER DATE CONSIDERED 9/20/03								

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.